The Role of MIR675 in Disease: Potential Drug Target and Biomarker (G100033819)
The Role of MIR675 in Disease: Potential Drug Target and Biomarker
MicroRNAs (miRNAs) have gained significant attention in recent years due to their regulatory functions in various physiological and pathological processes. Among these miRNAs, MIR675 has emerged as a promising candidate with potential implications in disease diagnosis and treatment. This article investigates the role of MIR675 as a disease drug target and biomarker, exploring its significance in different health conditions and its potential applications in clinical settings.
MIR675 in Disease: Basic Overview
MIR675 is a highly conserved, non-coding RNA molecule belonging to the miRNA family. It is encoded within the long non-coding RNA H19 gene, which is expressed during embryonic development and repressed in most adult tissues. However, recent studies have shed light on the re-expression of H19 and the generation of MIR675 in various disease states, suggesting a potential association between this miRNA and pathological conditions.
MIR675 as a Disease Drug Target
Aberrant expression of MIR675 has been observed in various types of cancer, making it an attractive target for therapeutic interventions. In hepatocellular carcinoma (HCC), MIR675 has been found to promote tumor growth and metastasis by inhibiting specific tumor suppressor genes. Targeting MIR675 through antisense oligonucleotides or small interfering RNAs (siRNAs) holds great potential in mitigating tumor progression and enhancing treatment outcomes.
In addition, MIR675 has been implicated in breast cancer, where it influences cancer cell proliferation, migration, and invasion. Silencing MIR675 in breast cancer models has exhibited promising anti-tumor effects, presenting MIR675 as a viable drug target.
2. Cardiovascular Diseases
Cardiovascular diseases (CVDs) remain a major global health concern, and miRNAs are emerging as important contributors to their pathology. MIR675 has been found to be dysregulated in multiple CVDs, including heart failure, myocardial infarction, and atherosclerosis. In heart failure patients, increased circulating levels of MIR675 have been detected, correlating with disease severity. Targeting MIR675 may offer potential therapeutic benefits by modulating cardiac remodeling, improving cardiac function, and reducing adverse outcomes in CVD patients.
3. Neurological Disorders
The intricate regulation of miRNAs in the nervous system is crucial for maintaining proper neuronal function. Dysregulation of MIR675 has been associated with several neurological disorders, including Alzheimer's disease and Parkinson's disease. In Alzheimer's disease, MIR675 levels are elevated in the brains of affected individuals, contributing to the progression of cognitive impairment. Inhibition of MIR675 has shown promise in preclinical models, providing a potential avenue for therapeutic intervention in this devastating disorder.
MIR675 as a Biomarker
1. Diagnostic Biomarker
The dysregulation of MIR675 in various diseases makes it a potential diagnostic biomarker. Detection of MIR675 levels in bodily fluids, such as blood or urine, could serve as a non-invasive method for disease diagnosis, complementing traditional diagnostic techniques. The quantification of MIR675 expression may aid in early disease detection, risk stratification, and monitoring treatment response, enhancing patient care and outcomes.
2. Prognostic Biomarker
In addition to its diagnostic potential, MIR675 has shown promise as a prognostic biomarker in certain diseases. Elevated MIR675 expression has been associated with poor clinical outcomes, such as decreased survival rates and increased likelihood of disease recurrence. Incorporating MIR675 assessment into clinical prognostic models may refine risk stratification, allowing for tailored treatment strategies and improved patient management.
The emerging role of MIR675 in disease pathogenesis and progression opens up exciting avenues for both therapeutic targeting and diagnostic applications. Further research is warranted to unravel the intricate regulatory network of MIR675 and explore its potential as a drug target and biomarker in a wide range of diseases. Harnessing the therapeutic potential of MIR675 may pave the way for personalized medicine approaches and revolutionize disease management strategies.
Protein Name: MicroRNA 675
More Common Targets
MIR676 | MIR708 | MIR711 | MIR718 | MIR720 | MIR744 | MIR759 | MIR760 | MIR761 | MIR762 | MIR764 | MIR873 | MIR874 | MIR875 | MIR876 | MIR877 | MIR885 | MIR887 | MIR888 | MIR889 | MIR890 | MIR891A | MIR891B | MIR892A | MIR892B | MIR920 | MIR921 | MIR924 | MIR933 | MIR934 | MIR935 | MIR936 | MIR937 | MIR938 | MIR939 | MIR940 | MIR941-1 | MIR941-2 | MIR941-3 | MIR941-4 | MIR942 | MIR943 | MIR944 | MIS18A | MIS18A-AS1 | MISFA | MKLN1-AS | MKNK1-AS1 | MKRN2OS | MLF1-DT | MLIP-AS1 | MLKL | MMAA | MMP21 | MMP24OS | MMP25-AS1 | MMP9 | MNX1 | MORF4L1P7 | MORN4 | MOV10L1 | MOXD2P | MPDU1-AS1 | MPHOSPH8 | MPZL3 | MRGPRX2 | MRGPRX3 | MRGPRX4 | MRLN | MROH7-TTC4 | MRPL23-AS1 | MRPL39 | MRPL50 | MRPS18CP7 | MRPS21 | MRPS30-DT | MRPS31P4 | MRPS31P5 | MSC-AS1 | MSH5-SAPCD1 | MSRB3-AS1 | MSS51 | MSTO2P | MTA1-DT | MTMR12 | MTND1P11 | MTND1P23 | MTND1P3 | MTND1P33 | MTND2P21 | MTND2P28 | MTND4P10 | MTND4P12 | MTND4P17 | MTND4P22 | MTND4P24 | MTND4P28 | MTND4P29 | MTND5P16 | MTND5P19